Oncology Institute Inc. (TOI)
Oncology Institute Statistics
Share Statistics
Oncology Institute has 75.56M shares outstanding. The number of shares has increased by 2.45% in one year.
| Shares Outstanding | 75.56M |
| Shares Change (YoY) | 2.45% |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | 19.48% |
| Shares Floating | 36.82M |
| Failed to Deliver (FTD) Shares | 9 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 247.97K, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 247.97K |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.67% |
| Short Ratio (days to cover) | 3.38 |
Valuation Ratios
The PE ratio is -0.36 and the forward PE ratio is -5.22. Oncology Institute's PEG ratio is 0.05.
| PE Ratio | -0.36 |
| Forward PE | -5.22 |
| PS Ratio | 0.06 |
| Forward PS | 0.2 |
| PB Ratio | 6.46 |
| P/FCF Ratio | -0.76 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Oncology Institute Inc. has an Enterprise Value (EV) of 236.77M.
| EV / Earnings | -3.66 |
| EV / Sales | 0.6 |
| EV / EBITDA | -4.4 |
| EV / EBIT | -3.94 |
| EV / FCF | -7.81 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 8.36.
| Current Ratio | 2.15 |
| Quick Ratio | 1.96 |
| Debt / Equity | 8.36 |
| Total Debt / Capitalization | 89.32 |
| Cash Flow / Debt | -0.88 |
| Interest Coverage | -8.02 |
Financial Efficiency
Return on equity (ROE) is -18.02% and return on capital (ROIC) is -178.87%.
| Return on Equity (ROE) | -18.02% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -178.87% |
| Revenue Per Employee | $476,863.03 |
| Profits Per Employee | $-78,379.39 |
| Employee Count | 825 |
| Asset Turnover | 2.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -27.85% in the last 52 weeks. The beta is 0.43, so Oncology Institute's price volatility has been higher than the market average.
| Beta | 0.43 |
| 52-Week Price Change | -27.85% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 0.47 |
| Relative Strength Index (RSI) | 64.39 |
| Average Volume (20 Days) | 814.82K |
Income Statement
In the last 12 months, Oncology Institute had revenue of 393.41M and earned -64.66M in profits. Earnings per share was -0.86.
| Revenue | 393.41M |
| Gross Profit | 393.41M |
| Operating Income | -60.12M |
| Net Income | -64.66M |
| EBITDA | -53.83M |
| EBIT | -60.12M |
| Earnings Per Share (EPS) | -0.86 |
Balance Sheet
The company has 49.67M in cash and 30.02M in debt, giving a net cash position of 19.65M.
| Cash & Cash Equivalents | 49.67M |
| Total Debt | 30.02M |
| Net Cash | 19.65M |
| Retained Earnings | -210.81M |
| Total Assets | 172.72M |
| Working Capital | 60.2M |
Cash Flow
In the last 12 months, operating cash flow was -26.54M and capital expenditures -3.79M, giving a free cash flow of -30.33M.
| Operating Cash Flow | -26.54M |
| Capital Expenditures | -3.79M |
| Free Cash Flow | -30.33M |
| FCF Per Share | -0.4 |
Margins
Gross margin is 100%, with operating and profit margins of -15.28% and -16.44%.
| Gross Margin | 100% |
| Operating Margin | -15.28% |
| Pretax Margin | -16.44% |
| Profit Margin | -16.44% |
| EBITDA Margin | -13.68% |
| EBIT Margin | -15.28% |
| FCF Margin | -7.71% |
Dividends & Yields
TOI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -75.44% |
| FCF Yield | -35.21% |
Analyst Forecast
The average price target for TOI is $2.5, which is 119.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 119.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 0.14 |
| Piotroski F-Score | 4 |